158 related articles for article (PubMed ID: 38006941)
1. Indigo naturalis (Qing dai) for inflammatory bowel disease: A systematic review and meta-analysis.
Kakdiya R; Jha DK; Choudhury A; Jena A; Sharma V
Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102250. PubMed ID: 38006941
[TBL] [Abstract][Full Text] [Related]
2. Short-term and long-term outcomes of indigo naturalis treatment for inflammatory bowel disease.
Matsuno Y; Hirano A; Torisu T; Okamoto Y; Fuyuno Y; Fujioka S; Umeno J; Moriyama T; Nagai S; Hori Y; Fujiwara M; Kitazono T; Esaki M
J Gastroenterol Hepatol; 2020 Mar; 35(3):412-417. PubMed ID: 31389626
[TBL] [Abstract][Full Text] [Related]
3. Ischemic colitis induced by indigo naturalis in a patient with ulcerative colitis: a case report.
Cho B; Yoon SM; Son SM; Kim HW; Kim KB; Youn SJ
BMC Gastroenterol; 2020 May; 20(1):154. PubMed ID: 32414334
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T;
Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Indigo Naturalis Therapy for Ulcerative Colitis: A Case Series.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Matsumoto T
Intern Med; 2019 Aug; 58(16):2299-2304. PubMed ID: 31118381
[TBL] [Abstract][Full Text] [Related]
6. Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn's disease.
Kim HA; Suh HR; Kang B; Choe BH;
Intest Res; 2019 Jan; 17(1):144-148. PubMed ID: 30317857
[TBL] [Abstract][Full Text] [Related]
7. Dramatically Improved Severe Pulmonary Arterial Hypertension Caused by Qing-Dai (Chinese Herbal Drug) for Ulcerative Colitis.
Kubota K; Imai Y; Okuyama T; Ishiyama Y; Ueno S; Kario K
Int Heart J; 2023; 64(2):316-320. PubMed ID: 37005323
[TBL] [Abstract][Full Text] [Related]
8. Treatment-refractory ulcerative colitis responsive to indigo naturalis.
Saiki JP; Andreasson JO; Grimes KV; Frumkin LR; Sanjines E; Davidson MG; Park KT; Limketkai B
BMJ Open Gastroenterol; 2021 Dec; 8(1):. PubMed ID: 34969665
[TBL] [Abstract][Full Text] [Related]
9. Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis.
Yokote A; Imazu N; Umeno J; Kawasaki K; Fujioka S; Fuyuno Y; Matsuno Y; Moriyama T; Miyawaki K; Akashi K; Kitazono T; Torisu T
J Gastroenterol; 2023 Sep; 58(9):868-882. PubMed ID: 37410250
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the anti-colitis activities of Qing Dai/Indigo Naturalis constituents in mice.
Ozawa K; Mori D; Hatanaka A; Sawano T; Nakatani J; Ikeya Y; Nishizawa M; Tanaka H
J Pharmacol Sci; 2020 Apr; 142(4):148-156. PubMed ID: 32033881
[TBL] [Abstract][Full Text] [Related]
11. From natural dye to herbal medicine: a systematic review of chemical constituents, pharmacological effects and clinical applications of indigo naturalis.
Qi-Yue Y; Ting Z; Ya-Nan H; Sheng-Jie H; Xuan D; Li H; Chun-Guang X
Chin Med; 2020 Dec; 15(1):127. PubMed ID: 33317592
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis: A Single-Center Open-Label Prospective Study.
Sugimoto S; Naganuma M; Kiyohara H; Arai M; Ono K; Mori K; Saigusa K; Nanki K; Takeshita K; Takeshita T; Mutaguchi M; Mizuno S; Bessho R; Nakazato Y; Hisamatsu T; Inoue N; Ogata H; Iwao Y; Kanai T
Digestion; 2016; 93(3):193-201. PubMed ID: 26959688
[TBL] [Abstract][Full Text] [Related]
13. Development of an Indigo Naturalis Suppository for Topical Induction Therapy in Patients with Ulcerative Colitis.
Yoshimatsu Y; Naganuma M; Sugimoto S; Tanemoto S; Umeda S; Fukuda T; Nomura E; Yoshida K; Ono K; Mutaguchi M; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Takabayashi K; Ogata H; Iwao Y; Kanai T
Digestion; 2020; 101(4):492-498. PubMed ID: 31238326
[TBL] [Abstract][Full Text] [Related]
14. Colitis with wall thickening and edematous changes during oral administration of the powdered form of Qing-dai in patients with ulcerative colitis: a report of two cases.
Kondo S; Araki T; Okita Y; Yamamoto A; Hamada Y; Katsurahara M; Horiki N; Nakamura M; Shimoyama T; Yamamoto T; Takei Y; Kusunoki M
Clin J Gastroenterol; 2018 Aug; 11(4):268-272. PubMed ID: 29549501
[TBL] [Abstract][Full Text] [Related]
15. Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation.
Kawai S; Iijima H; Shinzaki S; Hiyama S; Yamaguchi T; Araki M; Iwatani S; Shiraishi E; Mukai A; Inoue T; Hayashi Y; Tsujii M; Motooka D; Nakamura S; Iida T; Takehara T
J Gastroenterol; 2017 Aug; 52(8):904-919. PubMed ID: 27900483
[TBL] [Abstract][Full Text] [Related]
16. Fast Inspection of Quality of Indigo Naturalis by Multiple Light Scattering.
Liu X; Ye H; Huang H; Yang M; Han L; Xu R; Zhang D
J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607092
[TBL] [Abstract][Full Text] [Related]
17. The double-edged sword effect of indigo naturalis.
Xu Y; Lin C; Tan HY; Bian ZX
Food Chem Toxicol; 2024 Mar; 185():114476. PubMed ID: 38301993
[TBL] [Abstract][Full Text] [Related]
18. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study.
Naganuma M; Sugimoto S; Fukuda T; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Abe T; Suzuki Y; Kanai T;
J Gastroenterol; 2020 Feb; 55(2):169-180. PubMed ID: 31529220
[TBL] [Abstract][Full Text] [Related]
19. Treatment with indigo naturalis for inflammatory bowel disease and other immune diseases.
Naganuma M
Immunol Med; 2019 Mar; 42(1):16-21. PubMed ID: 31034341
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial.
Uchiyama K; Takami S; Suzuki H; Umeki K; Mochizuki S; Kakinoki N; Iwamoto J; Hoshino Y; Omori J; Fujimori S; Yanaka A; Mizokami Y; Ohkusa T
PLoS One; 2020; 15(11):e0241337. PubMed ID: 33151988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
